|
|
 | | | |
- close
- close
- close
- close
| |||||||||
This excerpt taken from the ELN 6-K filed Oct 27, 2005. Alzheimer’s and other Neurodegenerative Diseases
Elan is focused on building upon its breakthrough research and extensive experience in Alzheimer’s disease (AD) and is also studying other neurodegenerative diseases, such as Parkinson’s disease.
Two of our compounds from the Alzheimer’s disease immunotherapy program, in collaboration with Wyeth, are currently progressing through clinical trials.
12
Elan Third Quarter 2005 Financial Results
ACC-001 Following the acceptance of the Investigational New Drug Application for ACC-001, our active A-beta immunotherapeutic conjugate, we entered a phase I clinical trial and initiated dosing of patients in the third quarter of 2005. This twelve month clinical trial is designed to study safety and pharmacokinetics in patients with mild to moderate Alzheimer’s disease.
AAB-001 The phase II clinical trials with our humanized monoclonal antibody, AAB-001, designed and engineered to remove the neurotoxic beta-amyloid peptide that accumulates in the brain of patients with AD, is advancing as planned. Dosing was initiated in the first half of 2005 and is scheduled to last eighteen months, with several planned interim analyses.
This excerpt taken from the ELN 6-K filed Jul 28, 2005. Alzheimer’s and other Neurodegenerative Diseases
Elan is focused on building upon its breakthrough research and extensive experience in Alzheimer’s disease (AD) and is also studying other neurodegenerative diseases, such as Parkinson’s disease.
We continue to make progress with our Alzheimer’s disease immunotherapy program, in collaboration with Wyeth. During the first half of 2005, we initiated two Phase II clinical trials with a humanized monoclonal antibody, AAB-001, designed and engineered to remove the neurotoxic beta-amyloid peptide that accumulates in the brains of patients with AD. The first trial is a randomized, double-blind, placebo controlled, multiple ascending dose study of 180 patients with mild to moderate Alzheimer’s disease. The trial will be conducted at approximately 30 sites in the U.S. and dosing is scheduled for 18 months, with planned interim analyses. The key end-points will include ADAS-Cog (assesses cognition), Neuropsychological Test Battery (NTB) and DAD score (measures quality of
14
Elan Second Quarter 2005 Financial Results
life). The second trial is an Alzheimer’s beta-amyloid imaging study in 30 patients and dosing is scheduled for 18 months.
Elan and Wyeth are on track to initiate a Phase I trial, in the second half of this year, for ACC-001, an active Abeta immunotherapeutic conjugate.
Elan also has research programs focused on small molecule inhibitors of beta secretase and gamma secretase, enzymes whose actions are thought to affect the accumulation of amyloid plaques in the brains of patients with Alzheimer’s disease.
| EXCERPTS ON THIS PAGE:
RELATED TOPICS for ELN: |
| |||||||
